Vadalà M, Sunseri Trapani V, Guarrasi G, et al. - Researchers performed a prospective, non-comparative study to assess the effectiveness of a Pro Re Nata (PRN) regimen of DexI on diabetic macular edema (DME) and correlate treatment outcomes with inflammatory biomarkers. Participants in the study were 18 patients (24 eyes). Data reported that the mean duration of follow-up was 18 ± 6.6 months. The intravitreal dexamethasone implant was safe and effective in improving both functional and tomographic parameters in patients with DME. This finding is consistent with the improvement in biomarkers of inflammation. No major adverse effects have been observed.